Targeting dynamic hyperinflation in moderate-to-severe asthma: a randomised controlled trial

Area of Science:

• Pulmonology
• Respiratory Medicine
• Clinical Trials

Background:

• Dynamic hyperinflation is common in moderate-to-severe asthma, limiting daily activities.
• It is hypothesized to stem from airway inflammation and be reducible by anti-inflammatory treatments.

Purpose of the Study:

• To investigate the effect of systemic glucocorticoids on dynamic hyperinflation in asthma.
• To explore relationships between inflammatory markers and changes in dynamic hyperinflation.

Main Methods:

• A randomized placebo-controlled trial involving 32 asthma patients with dynamic hyperinflation.
• Patients received intramuscular triamcinolone or placebo, with assessments before and after 2 weeks of treatment.

Main Results:

• Triamcinolone significantly reduced dynamic hyperinflation by 28.1% (p=0.027).
• Reductions were more pronounced in patients with higher baseline blood eosinophils (r=-0.592, p=0.020).

Conclusions:

• Systemic anti-inflammatory treatment can reduce dynamic hyperinflation in asthma.
• Elevated blood eosinophils may predict treatment response, supporting airway inflammation as a key factor.